daptomycin

Summary

Summary: A lipopeptide antibiotic that inhibits gram-positive bacteria.

Top Publications

  1. pmc Genetic basis for daptomycin resistance in enterococci
    Kelli L Palmer
    Departments of Ophthalmology and Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 55:3345-56. 2011
  2. pmc Genetic basis for in vivo daptomycin resistance in enterococci
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    N Engl J Med 365:892-900. 2011
  3. pmc Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:526-31. 2011
  4. pmc In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates
    Nagendra N Mishra
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:4012-8. 2011
  5. pmc Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus
    Anton Y Peleg
    Department of Microbiology, School of Biomedical Sciences, Monash University, Melbourne, Australia
    PLoS ONE 7:e28316. 2012
  6. pmc Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
    Lisa Friedman
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:2137-45. 2006
  7. pmc An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
  8. pmc VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus
    Shrenik Mehta
    Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Antimicrob Agents Chemother 56:92-102. 2012
  9. pmc Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates
    Ute Bertsche
    Interfakultäres Institut für Mikrobiologie und Infektionsmedizin, Microbial Genetics, University of Tubingen, Tubingen, Germany
    PLoS ONE 8:e67398. 2013
  10. pmc Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
    Daniel J Skiest
    Baystate Medical Center, Division of Infectious Diseases, 759 Chestnut St, Springfield, MA 01199, USA
    J Clin Microbiol 44:655-6. 2006

Detail Information

Publications307 found, 100 shown here

  1. pmc Genetic basis for daptomycin resistance in enterococci
    Kelli L Palmer
    Departments of Ophthalmology and Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 55:3345-56. 2011
    ..The lipopeptide antibiotic daptomycin is approved to treat Gram-positive bacterial infections, including those caused by enterococci...
  2. pmc Genetic basis for in vivo daptomycin resistance in enterococci
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    N Engl J Med 365:892-900. 2011
    b>Daptomycin is a lipopeptide with bactericidal activity that acts on the cell membrane of enterococci and is often used off-label to treat patients infected with vancomycin-resistant enterococci...
  3. pmc Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:526-31. 2011
    ..study examined the relationship among CM carotenoid content, membrane order, and in vitro susceptibility to daptomycin or to prototypic neutrophil-derived, platelet-derived, or bacterium-derived cationic antimicrobial peptides (..
  4. pmc In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates
    Nagendra N Mishra
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:4012-8. 2011
    ..that methicillin-resistant Staphylococcus aureus (MRSA) isolates developing reduced susceptibilities to daptomycin (DAP; a calcium-dependent molecule acting as a cationic antimicrobial peptide [CAP]) may also coevolve reduced ..
  5. pmc Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus
    Anton Y Peleg
    Department of Microbiology, School of Biomedical Sciences, Monash University, Melbourne, Australia
    PLoS ONE 7:e28316. 2012
    b>Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the genetic evolution to daptomycin resistance in S. aureus.
  6. pmc Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
    Lisa Friedman
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:2137-45. 2006
    b>Daptomycin is a lipopeptide antibiotic with potent activity against gram-positive bacteria...
  7. pmc An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
    ..the establishment of a Staphylococcus aureus laboratory strain, 10 3d1, having reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype...
  8. pmc VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus
    Shrenik Mehta
    Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Antimicrob Agents Chemother 56:92-102. 2012
    b>Daptomycin (DAP) is a new class of cyclic lipopeptide antibiotic highly active against methicillin-resistant Staphylococcus aureus (MRSA) infections...
  9. pmc Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates
    Ute Bertsche
    Interfakultäres Institut für Mikrobiologie und Infektionsmedizin, Microbial Genetics, University of Tubingen, Tubingen, Germany
    PLoS ONE 8:e67398. 2013
    Multiple mechanisms have been correlated with daptomycin-resistance (DAP-R) in Staphylococcus aureus. However, one common phenotype observed in many DAP-R S. Aureus strains is a thickened cell wall (CW)...
  10. pmc Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
    Daniel J Skiest
    Baystate Medical Center, Division of Infectious Diseases, 759 Chestnut St, Springfield, MA 01199, USA
    J Clin Microbiol 44:655-6. 2006
    b>Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA)...
  11. ncbi Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:143-9. 2007
    ..Program during 2003-2004 to determine their susceptibility to several antimicrobial classes, including daptomycin. Daptomycin, vancomycin and teicoplanin minimum inhibitory concentrations (MICs) and minimum bactericidal ..
  12. pmc Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms
    Soo Jin Yang
    Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Antimicrob Agents Chemother 54:3079-85. 2010
    The mechanism(s) of daptomycin (DAP) resistance (DAPr) is incompletely defined...
  13. pmc Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus
    Soo Jin Yang
    Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    J Infect Dis 200:1916-20. 2009
    ..we investigated the transcriptional profiles of the mprF and dlt genes in the context of cell-surface charge and daptomycin nonsusceptibility...
  14. pmc Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, Torrance, California 90502, USA
    Antimicrob Agents Chemother 53:2312-8. 2009
    Our previous studies of clinical daptomycin-resistant (Dap(r)) Staphylococcus aureus strains suggested that resistance is linked to the perturbations of several key cell membrane (CM) characteristics, including the CM order (fluidity), ..
  15. pmc Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
    Jared A Silverman
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts 02421, USA
    Antimicrob Agents Chemother 47:2538-44. 2003
    The objective of this study was to further elucidate the role of membrane potential in the mechanism of action of daptomycin, a novel lipopeptide antibiotic...
  16. pmc Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization
    Arunachalam Muthaiyan
    Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790 4120, USA
    Antimicrob Agents Chemother 52:980-90. 2008
    b>Daptomycin is a lipopeptide antibiotic that has recently been approved for treatment of gram-positive bacterial infections. The mode of action of daptomycin is not yet entirely clear...
  17. pmc Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation
    Ute Bertsche
    Interfacultary Institute of Microbiology and Infection Medicine, Microbial Genetics, University of Tubingen, Auf der Morgenstelle 28, 72076 Tubingen, Germany
    Antimicrob Agents Chemother 55:3922-8. 2011
    Cell wall thickening is a common feature among daptomycin-resistant Staphylococcus aureus strains. However, the mechanism(s) leading to this phenotype is unknown...
  18. pmc Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 50:1079-82. 2006
    We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA)...
  19. pmc Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding
    Tiffanny Jones
    Los Angeles Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 225, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:269-78. 2008
    Increasingly frequent reports have described the in vivo loss of daptomycin susceptibility in association with clinical treatment failures. The mechanism(s) of daptomycin resistance is not well understood...
  20. pmc Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus
    Azzam Saleh-Mghir
    Département de Médecine Aiguë Spécialisée, Hopital Raymond Poincare, 104 boulevard Raymond Poincaré, 92380 Garches Cedex, France
    Antimicrob Agents Chemother 55:4589-93. 2011
    b>Daptomycin is an attractive option for treating prosthetic joint infection, but the 6-mg/kg of body weight/day dose was linked to clinical failure and emergence of resistance...
  21. pmc Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall
    Arnold S Bayer
    Los Angeles Biomedical Research Institute at Harbor University of California, Los Angeles, Torrance, California 905092, USA
    Ann N Y Acad Sci 1277:139-58. 2013
    The bactericidal, cell membrane-targeting lipopeptide antibiotic daptomycin (DAP) is an important agent in treating invasive Staphylococcus aureus infections...
  22. pmc Treatment of gram-positive deep sternal wound infections in cardiac surgery--experiences with daptomycin
    Aron F Popov
    Department of Thoracic Cardiovascular Surgery, University of Gottingen, Germany
    J Cardiothorac Surg 6:112. 2011
    ..The aim of the study is to quantify the application of daptomycin treatment of DSWI due to gram-positive organisms post cardiac surgery...
  23. pmc Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis
    Francisco M Marty
    Division of Infectious Diseases, Brigham and Women s Hospital, 75 Francis Street, PBB A4, Boston, MA 02115, USA
    J Clin Microbiol 44:595-7. 2006
    The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis...
  24. pmc In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus
    Yuhan Chang
    Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Antimicrob Agents Chemother 55:5480-4. 2011
    ..this study was to evaluate the antibacterial effects of polymethylmethacrylate (PMMA) bone cements loaded with daptomycin, vancomycin, and teicoplanin against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant ..
  25. pmc Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vi
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:2156-62. 2008
    ..45 to 1.3 logs). Overall, administration of daptomycin followed by vancomycin demonstrated the most significant kill against all strains in both models...
  26. ncbi In vitro bactericidal activity of daptomycin against staphylococci
    Peter C Fuchs
    The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070, USA
    J Antimicrob Chemother 49:467-70. 2002
    MICs and minimum bactericidal concentrations (MBCs) of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin (Q-D) were determined for 108 staphylococcal isolates. All strains were susceptible (MICs) to daptomycin (< or =2...
  27. ncbi Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study
    Carol L Moore
    Department of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA
    Clin Infect Dis 54:51-8. 2012
    ..Consensus guidelines recommend considering use of alternative agents for infections involving a higher vancomycin MIC, despite few data to support this approach...
  28. ncbi In silico aided metabolic engineering of Streptomyces roseosporus for daptomycin yield improvement
    Di Huang
    Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, People s Republic of China
    Appl Microbiol Biotechnol 94:637-49. 2012
    ..Overexpression of zwf2, dptI, and dptJ genes increased the daptomycin concentration up to 473.2, 452.5, and 489.1 mg/L, respectively...
  29. ncbi Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies
    Warren E Rose
    Anti Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, and Detroit Receiving Hospital, MI 48201, USA
    J Antimicrob Chemother 60:334-40. 2007
    A failure to daptomycin therapy and subsequent emergence of a daptomycin non-susceptible isolate occurred during the 1990 clinical investigation of daptomycin for the treatment of Staphylococcus aureus bacteraemia and endocarditis...
  30. pmc Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients
    Nagendra N Mishra
    Los Angeles Biomedical Research Institute
    J Infect Dis 206:1160-7. 2012
    We hypothesized that, for methicillin-resistant Staphylococcus aureus (MRSA), in vitro daptomycin susceptibility could be influenced by exposures to endogenous host defense peptides (HDPs) prior to clinical exposure to daptomycin.
  31. pmc Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure
    Susan Boyle-Vavra
    Department of Pediatrics, University of Chicago, KCBD 4152, 900 E 57th Street, Chicago, IL 60657, USA
    Antimicrob Agents Chemother 55:2018-25. 2011
    We describe here a clinical daptomycin treatment failure in a patient with recurrent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in whom daptomycin was administered after a failed empirical treatment course with ..
  32. ncbi Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 50:1568-74. 2010
    The objective of this analysis was to evaluate the relationship between daptomycin exposure and the probability of an elevation in the creatine phosphokinase (CPK) level (hereafter, "CPK elevation") in patients with Staphylococcus aureus ..
  33. ncbi Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia
    Peter E Pertel
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Clin Infect Dis 46:1142-51. 2008
    We sought to compare daptomycin with ceftriaxone for the treatment of patients with community-acquired pneumonia (CAP).
  34. pmc Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:3162-5. 2009
    Vancomycin and daptomycin MIC results for 1,800 randomly selected oxacillin (methicillin [meticillin])-resistant Staphylococcus aureus (MRSA) bloodstream isolates from nine U.S...
  35. ncbi Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus
    Helen W Boucher
    Division of Infectious Diseases, Tufts New England Medical Center, Boston, MA 02111, USA
    Clin Infect Dis 45:601-8. 2007
    ..Vancomycin has been associated with decreased susceptibility in staphylococci and with treatment failures. Daptomycin is rapidly bactericidal; a dosage of 4 mg/kg daily is approved for treatment of skin and soft-tissue infections, ..
  36. pmc The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion
    Christoph M Ernst
    Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tubingen, Tubingen, Germany
    PLoS Pathog 5:e1000660. 2009
    ..a crucial role in Staphylococcus aureus virulence and it is involved in resistance to the CAMP-like antibiotic daptomycin. MprF is a large membrane protein that modifies the anionic phospholipid phosphatidylglycerol with l-lysine, ..
  37. pmc Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype
    Ilana Lopes Baratella da Cunha Camargo
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 52:4289-99. 2008
    In order to better understand the mechanism of daptomycin resistance, we generated a daptomycin-nonsusceptible derivative strain, strain 10*3d1 (MIC = 3...
  38. ncbi Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:158-62. 2009
    ..to 2008 in hospitals located in the United States were tested by reference broth microdilution methods against daptomycin and comparison agents. Methicillin (oxacillin) resistance rates were 55.9% and 74...
  39. pmc Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 48:4665-72. 2004
    ..Staphylococcus aureus (MSSA and MRSA, respectively) on the activities of nafcillin, linezolid, vancomycin, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model with simulated endocardial ..
  40. ncbi Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program
    D A Figueroa
    Department of Pharmacy, New York Hospital Queens, Flushing, New York 11355, USA
    Clin Infect Dis 49:177-80. 2009
    There are limited safety data for high-dose and long-term daptomycin treatment (16mg/kg administered for >or=14 days). We present our experience in 61 patients.
  41. ncbi Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Vance G Fowler
    Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 355:653-65. 2006
    ..Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed...
  42. pmc Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
    Mark Benvenuto
    Cubist Pharmaceuticals, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:3245-9. 2006
    b>Daptomycin, a novel lipopeptide, is bactericidal against a broad range of gram-positive strains, including methicillin- (MRSA) and vancomycin-resistant Staphylococcus aureus...
  43. ncbi Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
    G L French
    Department of Infection, King s College London, St Thomas Hospital, London SE1 7EH, UK
    J Antimicrob Chemother 58:1107-17. 2006
    ..b>Daptomycin, the first of the cyclic lipopeptides, shows rapid bactericidal activity against S...
  44. pmc Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis
    Kathleen Julian
    Penn State Milton S Hershey Medical Center, Room C6833, BMR Bldg, Mailcode H036, 500 University Dr, Hershey, PA 17033, USA
    Antimicrob Agents Chemother 51:3445-8. 2007
    We analyzed the emergence of daptomycin nonsusceptibility in a patient with persistent vancomycin-intermediate Staphylococcus aureus (VISA) bacteremia...
  45. pmc Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo
    Elizabeth C Weiss
    Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Antimicrob Agents Chemother 53:4096-102. 2009
    ..sarA) has an impact on the susceptibility of established Staphylococcus aureus biofilms to treatment with daptomycin in vivo...
  46. pmc A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin
    Karla D Passalacqua
    Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia, USA
    Antimicrob Agents Chemother 56:5212-23. 2012
    ..In addition, the VISA isolate lost beta-lactamase activity and showed increased resistance to daptomycin and linezolid...
  47. pmc β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives
    Shrenik Mehta
    Department of Pathology and Genomic Medicine, The Methodist Hospital Research Institute, Houston, TX, USA
    Antimicrob Agents Chemother 56:6192-200. 2012
    ..b>Daptomycin (DAP) is a cyclic anionic lipopeptide recommended for treatment of skin infections, bacteremia, and right-sided ..
  48. ncbi Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin
    Praveena Marconescu
    Medical Care Line, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    Scand J Infect Dis 44:620-2. 2012
    ..time-kill assays to determine the in vitro killing rate of 22 strains of MRSA by vancomycin, telavancin, daptomycin, and ceftaroline...
  49. ncbi Strain improvement of Streptomyces roseosporus for daptomycin production by rational screening of He-Ne laser and NTG induced mutants and kinetic modeling
    Guanghai Yu
    Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, People s Republic of China
    Appl Biochem Biotechnol 163:729-43. 2011
    To improve the yield of daptomycin by Streptomyces roseosporus, a method of rational screening of He-Ne Laser and N-methyl-N-nitro-N-nitrosoguanidine (NTG)-induced mutants was employed in this work...
  50. ncbi Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases
    Becky A Miller
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA
    Clin Infect Dis 50:e63-8. 2010
    We describe 3 cases of daptomycin-induced pulmonary toxic effects that are consistent with drug-induced acute eosinophilic pneumonia...
  51. pmc Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins
    Joe Pogliano
    Division of Biological Sciences, University of California, San Diego, California, USA
    J Bacteriol 194:4494-504. 2012
    b>Daptomycin is a lipopeptide antibiotic used clinically for the treatment of certain types of Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA)...
  52. pmc Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis
    Denis Grandgirard
    Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Switzerland
    Antimicrob Agents Chemother 56:4289-95. 2012
    ..b>Daptomycin, a nonlytic antibiotic acting on Gram-positive bacteria, lessens inflammation and brain injury compared to ..
  53. pmc Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, California, United States of America
    PLoS ONE 7:e43958. 2012
    The lipopeptide antibiotic, daptomycin (DAP) interacts with the bacterial cell membrane (CM)...
  54. pmc Daptomycin as supportive treatment option in patients developing mediastinitis after open cardiac surgery
    Florian Weis
    Department of Anaesthesiology, University of Munich LMU, Marchioninistrasse 15, 81377, Munich, Germany
    J Cardiothorac Surg 7:81. 2012
    ..Within this study, we report the successful use of daptomycin as supportive therapy in patients developing mediastinitis after open cardiac surgery.
  55. pmc Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm
    Issam Raad
    The University of Texas M D Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, TX 77030, USA
    Antimicrob Agents Chemother 51:1656-60. 2007
    ..In this in vitro study, we investigated the efficacies of the newer antibiotics daptomycin, linezolid, and tigecycline, in comparison with those of vancomycin, minocycline, and rifampin, against ..
  56. pmc Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty
    Ivor Byren
    Nuffield Orthopaedic Centre, Oxford, United Kingdom
    Antimicrob Agents Chemother 56:5626-32. 2012
    ..of Staphylococcus aureus causing prosthetic joint infection (PJI) supports investigation of higher doses of daptomycin in the management of PJI...
  57. ncbi Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin
    Jennifer D Twilla
    Methodist University Hospital, Memphis, TN 38104, USA
    J Hosp Med 7:243-8. 2012
    ..The purpose of this study was to assess clinical and microbiologic outcomes associated with the use of linezolid or daptomycin in the treatment of VRE bacteremia.
  58. pmc A current perspective on daptomycin for the clinical microbiologist
    Romney M Humphries
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California, USA
    Clin Microbiol Rev 26:759-80. 2013
    b>Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-positive bacteria that was first approved for clinical use in 2004 in the United States...
  59. pmc Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    C Garrigós
    Laboratory of Experimental Infection, Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain
    Antimicrob Agents Chemother 57:606-10. 2013
    The efficacy of daptomycin, imipenem, or rifampin with fosfomycin was evaluated and compared with that of daptomycin-rifampin in a tissue cage model infection caused by methicillin-resistant Staphylococcus aureus (MRSA)...
  60. pmc Lysyl-phosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance
    Erin Kilelee
    Department of Chemistry and Biochemistry, University of North Carolina Wilmington, Wilmington, North Carolina 28403, USA
    Antimicrob Agents Chemother 54:4476-9. 2010
    ..membranes has been linked to increased resistance to cationic compounds, including antibiotics such as daptomycin as well as host defense antimicrobial peptides...
  61. ncbi Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study
    Kyle P Murray
    Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA
    Clin Infect Dis 56:1562-9. 2013
    ..Recent reports have described decreased effectiveness with vancomycin treatment for methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) when the vancomycin minimum inhibitory concentration (MIC) is >1 µg/mL...
  62. ncbi Non-ribosomal peptide synthetase module fusions to produce derivatives of daptomycin in Streptomyces roseosporus
    Sascha Doekel
    Cubist Pharmaceuticals Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Microbiology 154:2872-80. 2008
    ..a di-modular NRPS subunit that incorporates 3-methylglutamic acid (3mGlu(12)) and kynurenine (Kyn(13)) into daptomycin. Mutations causing amino acid substitutions, deletions or insertions in the inter-module linker had no negative ..
  63. pmc Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model
    Brian J Werth
    Anti Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA
    Antimicrob Agents Chemother 57:66-73. 2013
    ..serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to daptomycin and vancomycin...
  64. ncbi Characterization of daptomycin-loaded antibiotic cement
    Lige Kaplan
    Department of Orthopaedic Surgery, Beaumont Health System, Royal Oak, Michigan 48073, USA
    Orthopedics 35:e503-9. 2012
    ..The purpose of this study was to characterize the release of daptomycin from PMMA cement and the subsequent effects on mechanical properties...
  65. ncbi A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria
    D E Katz
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Int J Clin Pract 62:1455-64. 2008
    ..The bactericidal antibiotic daptomycin is approved for gram-positive cSSSI at 4 mg/kg/day for 7-14 days, but the optimal dose level and duration of ..
  66. ncbi Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 64:1024-8. 2009
    The bactericidal activities of vancomycin and daptomycin were evaluated in a large collection of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia strains from nine major USA medical centres.
  67. pmc Clinical experience with daptomycin in Europe: the first 2.5 years
    Armando Gonzalez-Ruiz
    Microbiology Department, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK
    J Antimicrob Chemother 66:912-9. 2011
    To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes.
  68. ncbi LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF
    Aileen Rubio
    Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA
    Mol Membr Biol 29:1-8. 2012
    b>Daptomycin (DAP) is a cyclic lipopeptide antibiotic used for the treatment of certain Staphylococcus aureus infections. Although rare, strains have been isolated that are DAP resistant...
  69. pmc Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach
    Adrien Fischer
    Genomic Research Laboratory, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland
    J Antimicrob Chemother 66:1696-711. 2011
    The development of daptomycin resistance in Staphylococcus aureus is associated with clinical treatment failures. The mechanism(s) of such resistance have not been clearly defined.
  70. ncbi Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections
    Friederike Traunmüller
    Department of Surgery, Division of Plastic Surgery, Medical University of Graz, Auenbruggerplatz 29, A 8036 Graz, Austria
    J Antimicrob Chemother 65:1252-7. 2010
    In the attempt to overcome increasing glycopeptide- and methicillin-resistant soft tissue infections, daptomycin is presently considered as an attractive alternative to the class of glycopeptides...
  71. ncbi In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium
    Laura A Jevitt
    Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
    Microb Drug Resist 9:389-93. 2003
    We assessed the in vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin (QD) against a contemporary challenge panel of 88 staphylococcal and 90 enterococcal isolates...
  72. pmc Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis
    Anna Barbara Hachmann
    Department of Microbiology, Wing Hall, Cornell University, Ithaca, NY 14853 8101, USA
    Antimicrob Agents Chemother 55:4326-37. 2011
    b>Daptomycin (DAP) is a cyclic lipopeptide that disrupts the functional integrity of the cell membranes of Gram-positive bacteria in a Ca(2+)-dependent manner...
  73. ncbi High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study
    Ravina Kullar
    Anti Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA
    Pharmacotherapy 31:527-36. 2011
    To evaluate the clinical response and safety of high-dose daptomycin for treatment of complicated gram-positive infections.
  74. ncbi Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry
    J A Crompton
    Cubist Pharmaceuticals, Lexington, MA 02421, USA
    J Chemother 21:414-20. 2009
    ..Limited data is available describing the long-term safety and efficacy of daptomycin. the safety population was drawn from CORE 2005 and 2006, a retrospective, observational, multicenter study...
  75. ncbi In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms
    Bruna Leite
    IBB Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710 057 Braga, Portugal
    Curr Microbiol 63:313-7. 2011
    ..b>Daptomycin and linezolid belong to the novel antibiotic therapies that are active against gram-positive cocci...
  76. pmc Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin
    Manjunath P Pai
    College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 87131 0001, USA
    Antimicrob Agents Chemother 51:2741-7. 2007
    The present study characterized the single-dose pharmacokinetics of daptomycin dosed as 4 mg/kg of total body weight (TBW) in seven morbidly obese and seven age-, sex-, race-, and serum creatinine-matched healthy subjects...
  77. ncbi High-dose daptomycin in documented Staphylococcus aureus infections
    Matteo Bassetti
    Infectious Diseases Division, San Martino Hospital and University of Genoa School of Medicine, Genoa, Italy
    Int J Antimicrob Agents 36:459-61. 2010
    b>Daptomycin is approved at a dose of 4-6 mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection...
  78. ncbi Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis
    Mark Bounthavong
    Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA
    Value Health 14:631-9. 2011
    ....
  79. pmc Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin
    Anne Kathrin John
    Infectious Diseases Service, Department of Internal Medicine, University Hospital and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:2719-24. 2009
    ..We compared the activity of daptomycin (alone and with rifampin [rifampicin]) with the activities of other antimicrobial regimens against MRSA ATCC ..
  80. ncbi Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis
    Mark S Rouse
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Antimicrob Chemother 57:301-5. 2006
    ..b>Daptomycin is a cyclic lipopeptide anti-infective with activity against MRSA, approved for treatment of complicated skin ..
  81. pmc Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
    Warren E Rose
    Department of Pharmacy Practice, Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit Receiving Hospital, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:3061-7. 2008
    ..We evaluated the impact of simulated standard- and high-dose daptomycin in combination with gentamicin or rifampin against daptomycin-susceptible and nonsusceptible matched strains of ..
  82. ncbi Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years
    Maria D Appleman
    Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Diagn Microbiol Infect Dis 66:441-4. 2010
    We investigated vancomycin and daptomycin efficacy for Staphylococcus aureus isolates at our institution by testing 221 methicillin-sensitive and 299 methicillin-resistant isolates recovered from serious infections between 1979 and 2007 ..
  83. pmc Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA
    Int J Antimicrob Agents 33:564-8. 2009
    ..aureus (MRSA) bacteraemia developed endocarditis, failed a second course of vancomycin and then failed daptomycin therapy...
  84. ncbi Daptomycin: a review 4 years after first approval
    Robert Sauermann
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    Pharmacology 81:79-91. 2008
    b>Daptomycin is the first approved member of a new class of antibiotics, namely the cyclic lipopeptides. Daptomycin has rapid bactericidal activity against Gram-positive pathogens...
  85. pmc Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    O Murillo
    Laboratory of Experimental Infection, Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s n, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Antimicrob Agents Chemother 53:4252-7. 2009
    Since the currently approved dose of daptomycin (6 mg/kg of body weight/day) has been associated with clinical failures and resistance development, higher doses for some difficult-to-treat infections are being proposed...
  86. pmc Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model
    Molly Steed
    Anti Infective Research Laboratory, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 55:3522-6. 2011
    ..potential role of ceftaroline, a new broad-spectrum cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections...
  87. pmc Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations
    Molly E Steed
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA
    Antimicrob Agents Chemother 54:5187-92. 2010
    Reduced susceptibility to daptomycin has been reported in patients with infections due to methicillin-resistant Staphylococcus aureus (MRSA)...
  88. ncbi Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis
    M Lefebvre
    Universite de Nantes, Faculte de Medecine, EA3826, 1 rue Gaston Veil, F 44035 Nantes, France
    Int J Antimicrob Agents 36:542-4. 2010
    b>Daptomycin exhibits rapid bactericidal activity against Gram-positive organisms, including meticillin-resistant Staphylococcus aureus (MRSA). Daptomycin in combination with rifampicin needs to be assessed in bone infection...
  89. pmc Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    C Garrigós
    Infectious Diseases Service, Hospital Universitari de Bellvitge, Feixa Llarga s n, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Antimicrob Agents Chemother 54:5251-6. 2010
    ..The aim of this study was to evaluate the efficacies of daptomycin at usual and high doses (equivalent to 6 and 10 mg/kg of body weight/day, respectively, in humans) and in ..
  90. ncbi Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus
    Esteban Nannini
    Division of Infectious Diseases, School of Medicine, Universidad Nacional de Rosario, Rosario, Argentina
    Curr Opin Pharmacol 10:516-21. 2010
    ..Nonsusceptibility to daptomycin has been associated with changes in the structure and function of the cell envelope and surface charge...
  91. pmc Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")
    Soo Jin Yang
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, RB 2, Rm 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 54:3161-9. 2010
    In vivo development of daptomycin resistance (DAPr) among Staphylococcus aureus strains, especially methicillin-resistant S. aureus (MRSA) strains, in conjunction with clinical treatment failures, has emerged as a major problem...
  92. pmc A potential role for daptomycin in enterococcal infections: what is the evidence?
    Rafael Canton
    Servicio de Microbiologia, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain
    J Antimicrob Chemother 65:1126-36. 2010
    ..b>Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections...
  93. ncbi Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy
    Pamela A Moise
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    Ann Pharmacother 43:1211-9. 2009
    b>Daptomycin is approved for the treatment of skin and skin-structure infections (4 mg/kg) and Staphylococcus aureus bacteremia, including right-sided endocarditis (6 mg/kg)...
  94. pmc Daptomycin in experimental murine pneumococcal meningitis
    Barry B Mook-Kanamori
    Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
    BMC Infect Dis 9:50. 2009
    b>Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis...
  95. ncbi Daptomycin: mechanisms of action and resistance, and biosynthetic engineering
    Richard H Baltz
    Discovery Biology, Cubist Pharmaceuticals, Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Curr Opin Chem Biol 13:144-51. 2009
    b>Daptomycin is a lipopeptide antibiotic used clinically to treat infections caused by Gram-positive bacteria. Laboratory studies have shown that Staphylococcus aureus resistance to daptomycin occurs stepwise and slowly...
  96. pmc Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:4127-32. 2009
    ..We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference ..
  97. ncbi Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic
    Sara E Cosgrove
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 48:713-21. 2009
    ..This study evaluated the association between this practice and nephrotoxicity...
  98. ncbi Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE)
    John F Mohr
    Cubist Pharmaceuticals, Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Int J Antimicrob Agents 33:543-8. 2009
    ..Studies in vitro as well as animal and case studies suggest that daptomycin may be effective in enterococcal infections...
  99. ncbi Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate
    Madhukiran H Murthy
    Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA
    J Med Microbiol 57:1036-8. 2008
    b>Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA)...
  100. ncbi Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    Clin Infect Dis 52:228-34. 2011
    b>Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA)...
  101. pmc Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF
    Satish K Pillai
    Department of Infectious Disease, Cleveland Clinic Foundation, Mailstop S32, Cleveland, OH 44195, USA
    Antimicrob Agents Chemother 51:2223-5. 2007
    A previous study documented the presence of mutations in mprF that accompanied the loss of daptomycin susceptibility among Staphylococcus aureus isolates following exposure to the drug...

Research Grants25

  1. Molecular Mechanisms Of Daptomycin Resistance In Enterococci
    CESAR AUGUSTO ARIAS; Fiscal Year: 2013
    ..b>Daptomycin (DAP) is a lipopeptide antibiotic whose mechanism of killing involves the interaction with the bacterial cell ..
  2. Defining evolutionary trajectories: Molecular adaptation to antibiotic resistance
    ADIL YOUSIF SHAMOO; Fiscal Year: 2013
    ..a scalable and holistic approach that we call 'Quantitative Evolutionary Dynamics'(QED) to study daptomycin and tigecycline resistance in clinical isolates of vancomycin-resistant enterococci (VRE) and to tigecycline ..
  3. Biosynthesis of Antifungal Lipopeptides from Filamentous Fungi
    Yi Tang; Fiscal Year: 2013
    ..Newly approved lipo-NRPs such as daptomycin and anidulafungin (a semisynthetic derivative of echinocandin B, the target of this proposal) are important ..
  4. 2011 Staphyloccocal Diseases Gordon Research Conference
    Vance G Fowler; Fiscal Year: 2011
    ..The identification of S. aureus isolates resistant to vancomycin, linezolid, and daptomycin, indicates the possibility of a pathogen resistant to all available therapy...
  5. Mechanisms of Staphylococcal Co-Resistance to Daptomycin and Host Defense Peptide
    Arnold S Bayer; Fiscal Year: 2013
    ..Since FDA approval in 2003, daptomycin (DAP) has been utilized in many clinical settings, especially for recalcitrant methicillin-resistant SA (MRSA) ..
  6. Drug Discovery from Slow Growing and Rare Microbial Species
    Amy Spoering; Fiscal Year: 2013
    ..tuberculosis. Only 3 novel antibiotics have been introduced in the past thirty years - linezolid, daptomycin, and fidaxomicin...
  7. Genetics of vancomycin intermediate resistance in S. aureus
    Timothy D Read; Fiscal Year: 2011
    ..All strains will be tested for cross-resistance to an extended panel of drugs, including daptomycin and linezolid. More than 250 laboratory mutants of vancomycin susceptible (VSSA) S...
  8. Impact of Daptomycin Dose Exposure on Enterococci and Characterization of Resista
    Michael Joseph Rybak; Fiscal Year: 2012
    ..b>Daptomycin, a novel lipopeptide antibiotic, has activity against VRE...
  9. CYTOMETRY-AIDED DEVELOPMENT OF ANTIMICROBIAL AGENTS
    Howard Shapiro; Fiscal Year: 2001
    ..measurement of tetracycline uptake and efflux in bacteria, and detection of effects of tetracyclines and daptomycin on membrane potential, pH, and permeability...
  10. Role of Membrane Fluidity in S. aureus Antimicrobial Susceptibility
    BRIAN WILKINSON; Fiscal Year: 2009
    ..This will be studied in pine oil cleaner- and daptomycin-resistant strains...
  11. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2003
    The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and ..
  12. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2005
    The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and ..
  13. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
    ..Ciprofloxacin or daptomycin will be used as comparitors, and synergies with the furanones explored as well...
  14. Structure activity relationships around lipopeptides
    Paul Brian; Fiscal Year: 2003
    ..The most notable lipopeptide from the 10-membered ring group is daptomycin that is currently progressing through clinical trials...
  15. Enterococcus faecium virulence: A molecular and therapeutic approach
    Cesar Arias; Fiscal Year: 2008
    ..A translational approach using the mentor's laboratory established animal models (mouse peritonitis and rat infective endocarditis) will be utilized to explore therapeutic approaches. [unreadable] [unreadable] [unreadable]..
  16. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    SARA ELIZABETH COSGROVE; Fiscal Year: 2010
    ..We hypothesize that this approach will enhance appropriate use of antimicrobials for both VAP and CAUTI and improve patient outcomes by reducing the known sequelae of antimicrobial overuse. ..
  17. Proline uptake in staphylococcus aureus pathogenesis
    WILLIAM SCHWAN; Fiscal Year: 2002
    ..The results of this study will help us understand the role of proline transport in S. aureus infections. ..
  18. OmpR and acid regulation of Escherichia coli fim genes
    WILLIAM SCHWAN; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  19. Novel antibacterial agents for treatment of Tularemia
    Nachum Kaplan; Fiscal Year: 2004
    ..tularensis microbiological data and animal model data to warrant inclusion of the information on the product label as a narrow spectrum agent that could be used in the event of a F. tularensis release. ..
  20. Cytology and function of ParA in E. coli
    JOSEPH A POGLIANO; Fiscal Year: 2010
    ..The findings from this analysis of a representative ParAB plasmid partitioning system should have wide implications for our understanding of plasmid and chromosome segregation. ..
  21. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2003
    ..To augment information about where PBPs localize, when they are expressed during the cell cycle will be determined by Northern blotting. ..
  22. FUNGAL PROTEIN/GLYCOPROTEIN EXPRESSION IN TINEA CAPITIS
    Susan Abdel Rahman; Fiscal Year: 2003
    ..abstract_text> ..
  23. Evaluating Trichophyton tonsurans Carriage and Infection
    Susan Abdel Rahman; Fiscal Year: 2006
    ..abstract_text> ..
  24. Genetic Basis of Virulence of Community MRSA Clone USA300
    Henry F Chambers; Fiscal Year: 2010
    ..By knocking each of these genes out and testing for loss of virulence, we hope to learn which genes code for virulence. Once these genes are identified, strategies to block their effects may be developed. ..
  25. Intra-species regulatory functions of fsr
    Satish Pillai; Fiscal Year: 2004
    ..abstract_text> ..